



Mark Su, MD, MPH, FACEP, FACMT, FAACT

Please share your current and past involvement in AACT, AACT-related activities and/or ABAT.

Within AACT, I have served as a Board of Trustees member (since 2021) and as Chair/Co-Chair of the Scientific Review Committee (since 2023). In this role, I helped shape the organization's research agenda and mentorship efforts. I have co-organized multiple educational initiatives, including national webinars on toxicology research and fundamentals, where I also served as a lecturer in biostatistics, emphasizing a focus on strengthening methodological rigor in the field. Additionally, I have worked as Co-Coordinator of the Antidote Collective Committee highlighting my engagement in collaborative, practice-oriented initiatives addressing antidote use and shortages.

My NACCT participation over the years has been robust since I have contributed as a peer reviewer for annual scientific meeting abstracts over multiple years and have been involved in the planning of the NACCT meeting. My scholarly contributions include multiple oral presentations at NACCT, spanning clinical toxicology, epidemiology, and outcomes research. These presentations, along with my mentorship and abstract review work, demonstrate a consistent commitment to advancing the scientific quality and impact of the NACCT meeting.

Please note any previous leadership and/or board experience(s) in other associations and/or institutions.

See above.

Please share your vision and goals as a member of the Board of Trustees.

My vision for AACT is to strengthen its role as a national leader in toxicology research and education by building infrastructure that meaningfully improves the quality of evidence in our field. Central to this is the development of an AACT research consult service that provides members with accessible expertise in study design, biostatistics, and epidemiology, helping to move projects from concept to high-quality abstract and publication. In parallel, I aim to expand AACT's educational offerings into a structured, longitudinal curriculum in research methods that can be integrated into fellowship training and national programming.

I also envision fostering improvement in the research culture toward more rigorous, prospective, and collaborative studies by leveraging AACT's networks and the Scientific Review Committee to promote methodological excellence. Building on the success of the Antidote Collective, there is an opportunity to further develop it into a data-driven, multicenter collaborative that addresses antidote access and informs policy at a systems level. Together, these efforts will help create a sustainable pipeline of clinician-investigators and position AACT as a leading authority in research and evidence-based toxicology.

Professional Bio (150–200 words; will be used for the program/website)

Mark K. Su, MD, MPH, FACEP, FACMT, FAACT, is a board-certified emergency physician and medical toxicologist serving as Director of the New York City Poison Control Center and an attending physician in Emergency Medicine at NYU/Bellevue Hospital Center. He holds academic appointments as Clinical Associate Professor of Emergency Medicine at New York University School of Medicine and Affiliate Assistant Clinical Professor at St. John's University College of Pharmacy and Health Sciences. Dr. Su completed his medical degree at SUNY Downstate, residency in emergency medicine at SUNY Downstate, and fellowship in medical toxicology at NYU/New York City Poison Control Center, followed by an MPH in biostatistics from Columbia University.

Dr. Su has an extensive record of scholarship in clinical toxicology, epidemiology, and research methodology, and serves as a senior statistical editor for the "Journal of Medical Toxicology." He is an active leader within the American Academy of Clinical Toxicology, currently serving on the Board of Trustees and as Chair/Co-Chair of the Scientific Review Committee, and has helped develop national educational initiatives including research-focused webinars and the Antidote Collective. His work focuses on advancing evidence-based toxicology and improving the scientific rigor of Toxicology.